Indications and uses
Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials.
Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials.
use as directed by public officials in the event of a nuclear radiation emergency do not take more than 1 dose in 24 hours tablets can be whole or crushed and mixed in milk, baby formula, water, orange juice, flat soda like cola, or raspberry syrup The liquid mixture should be given to infants, young children, and others who cannot swallow tablets; see consumer package insert on how to make a liquid mixture. Age D...
Store at 20-25°C (68-77°F). Keep dry and foil intact.
Potassium iodide 130 mg
Thyroid blocking
Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials.
Allergy alert:Iodine may cause an allergic reaction with 1 or more of the following symptoms:
In case of overdose, get medical help or contact a Poison Control Center right away.
The liquid mixture should be given to infants, young children, and others who cannot swallow tablets; see consumer package insert on how to make a liquid mixture.
| Age | Dose |
| Adults over 18 years | 1 tablet (whole or crushed) daily (130 mg) |
| Children over 12 years to 18 years who weigh at least 150 pounds | 1 tablet (whole or crushed) daily (130 mg) |
| Children over 12 years to 18 years who weigh less than 150 pounds | 1/2 tablet (whole or crushed) daily (65 mg) |
| Children over 3 years to 12 years | 1/2 tablet (whole or crushed) daily (65 mg) |
| Children over 1 month to 3 years | 32.5 mg daily as directed in the consumer package insert |
| Birth to 1 month | 16.25 mg daily as directed in the consumer package insert |
magnesium stearate, microcrystalline cellulose, silica gel, sodium thiosulfate
call toll free 1-866-463-6754
ANBEX INC.
1812 West Sunset Blvd, Suite 1A-618
St George, UT 84770
(833) 467-2854
IOSAT™
(Potassium Iodide Tablets USP, 130 mg)
(Abbreviated KI)
Take potassium iodide (KI) only when public officials tell you. In a nuclear radiation emergency, radioactive iodine could be released into the air. KI protects only the thyroid gland from uptake of radioactive iodine. Therefore, KI should be used along with other emergency measures that will be recommended to you by public officials. If you are told to take this medicine, take it 1 time every 24 hours. Do not take it more often. More KI will not help you. Too much KI may increase the chances of side effects. Do not take this medicine if you know you are allergic to iodine (see SIDE EFFECTS below).
Each white, round, cross-scored—the name IOSAT stamped on one side—tablet contains 130 mg of potassium iodide.
IOSAT™(Potassium Iodide tablets, USP, 130 mg) is a thyroid blocking medicine that is used in a nuclear radiation emergency only.
Use only as directed by public officials if a nuclear radiation emergency happens.
| Age | Dose |
| Adults over 18 years | 1 tablet (whole or crushed) every day (130 mg) |
| Children over 12 years to 18 years who weigh at least 150 pounds | 1 tablet (whole or crushed) every day (130 mg) |
| Children over 12 years to 18 years who weigh less than 150 pounds | 1/2 tablet (whole or crushed) every day (65 mg) |
| Children over 3 years to 12 years | 1/2 tablet (whole or crushed) or 4 teaspoonfuls every day (65 mg) |
| Children over 1 month to 3 years | 2 teaspoonfuls every day (32.5 mg) |
| Birth to 1 month | 1 teaspoonful every day (16.25 mg) |
Tablets can be crushed and mixed in many liquids. To take the tablet in liquid solution, use dosing directions under Making a Potassium Iodide Liquid Mixture.
Take KI every day (every 24 hours) as directed by public officials. Do not take more than 1 dose in 24 hours. More will not help you. Too much medicine may increase the chances of side effects.
Making a Potassium Iodide Liquid Mixture:
The amount of KI (130 mg tablet) in the drink when mixed as described above is 16.25 mg per teaspoonful. The number of teaspoonfuls of the drink to give your child depends on your child’s age as described in the following table:
| Child's Age | Give your child this amount in teaspoonfuls |
| Over 12 years to 18 years who weigh less than 150 pounds | 4 teaspoonfuls will give you a 65 mg dose |
| Over 3 years to 12 years old | 4 teaspoonfuls will give you a 65 mg dose |
| Over 1 month to 3 years old | 2 teaspoonfuls will give you a 32.5 mg dose |
| Birth to 1 month | 1 teaspoonful will give you a 16.25 mg dose |
Note: This is the amount to give your child for onesingle dose in teaspoonfuls(not tablespoonfuls). You should give your child one dose each day as recommended by the public officials.
Pregnant or breastfeeding women, or babies under 1 month of age:Take as directed above and call a doctor as soon as possible. Repeat dosing should be avoided. It is recommended that thyroid function be checked in babies less than 1 month of age that take KI. Women who are pregnant or breastfeeding should also be checked by a doctor if repeat dosing is necessary. Although these precautions should be taken, the benefits of short-term use of KI to block uptake of radioactive iodine by the thyroid gland far exceed its chances of side effects.
Patients with thyroid disease:If you have both a nodular thyroid condition such as multinodular goiter with heart disease, you should not take KI. Patients with other thyroid conditions may take KI as directed above, but call a doctor if you need to take KI for more than a few days.
People who are allergic to iodine, have dermatitis herpetiformis or hypocomplementemic vasculitis, or have nodular thyroid disease with heart disease should not take KI. Keep out of the reach of children. In case of an allergic reaction (difficulty breathing, speaking or swallowing; wheezing; shortness of breath or swelling of the mouth or throat), call 911 or get medical care right away. In case of overdose, get medical help or call a Poison Control Center right away.
Certain forms of iodine help your thyroid gland work right. Most people get the iodine they need from foods like iodized salt or fish. The thyroid can “store” or hold only a certain amount of iodine.
In nuclear radiation emergency, radioactive iodine may be released in the air. This material may be breathed or swallowed. It may enter the thyroid gland and damage it. The damage would probably not show itself for years. Children are most likely to have thyroid damage.
If you take KI, it will block or reduce the chances that radioactive iodine will enter your thyroid gland.
People should avoid KI if they are allergic to iodine, have dermatitis herpetiformis or hypocomplementemic vasculitis, or have nodular thyroid disease with heart disease, because these conditions may increase the chances of side effects to iodine.
KI should be taken as soon as possible after public officials tell you. If you are told to repeat the dose, you should take the second dose 24 hours after the first dose. Do not take it sooner. More KI will not help you because the thyroid can “hold” only certain amounts of iodine. Taking more than 1 dose per day will increase the chances of side effects. The public officials will tell you how many days to take KI. You should take KI until the chances of major exposure to radioactive iodine by breathing or swallowing stops.
Short-term use of KI at the recommended dose is safe. You should not take this drug for longer than you are told.
Possible side effects include: swelling of the salivary glands, nausea, vomiting, diarrhea, stomach ache, fever, headache, metallic taste, and allergic reactions. Allergic reaction can include
Get medical attention right away if you have trouble breathing, speaking or swallowing; wheezing; shortness of breath; or swelling of the mouth, tongue or throat.
Taking iodide, in rare cases, may cause overactivity of the thyroid gland, underactivity of the thyroid gland, or enlargement of the thyroid gland (goiter). Symptoms of an overactive thyroid gland may include an irregular heartbeat and chest pain. Patients with thyroid disease are more likely to get these side effects. Babies under 1 month of age are more likely to get an underactive thyroid gland (hypothyroidism).
IOSAT™(Potassium Iodide Tablets, USP 130 mg) Each white, round tablet, cross-scored on one side and the IOSAT name on the other, contains 130 mg potassium iodide.
NDC 51803-001-01: 14 Unit dose, Foil Sealed, 130 mg Tablets.
NDC 51803-001-10: 10 X 14 Unit dose, Foiled Sealed 130 mg tablets (140 tablets) in a Clear Plastic Bag.
Also available:IOSAT™(Potassium Iodide Tablets, USP 65 mg) Packages of 20 tablets. Each white, round tablet, cross-scored on one side and the IOSAT name on the other, contains 65 mg potassium iodide.
NDC 51803-002-01: 2 X 10 Unit dose, Foil Sealed, 65 mg Tablets (20 Tablets).
Store at 20-25°C (68-77°F). Keep dry and foil intact.
ANBEX INC.
1812 West Sunset Blvd, Suite 1A-618
St George, UT 84770
(833) 467-2854
www.anbex.com
www.iosat.com
SH905-1
8/23
IOSAT™ (Potassium Iodide Tablets, USP 130 mg)
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1111703 | Iosat 130 MG Oral Tablet | PSN | 12 |
| 312539 | potassium iodide 130 MG Oral Tablet | PSN | 12 |
| 1111703 | potassium iodide 130 MG Oral Tablet [Iosat] | SBD | 12 |
| 312539 | potassium iodide 130 MG Oral Tablet | SCD | 12 |
| 1111703 | Iosat 130 MG Oral Tablet | SY | 12 |
| 312539 | K+ Iodide 130 MG Oral Tablet | SY | 12 |
| 1111703 | K+ Iodide 130 MG Oral Tablet [Iosat] | SY | 12 |
| 312539 | Pot Iodide 130 MG Oral Tablet | SY | 12 |
| 1111703 | Pot Iodide 130 MG Oral Tablet [Iosat] | SY | 12 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51803-001-01 | IOSAT | 14 in 1 PACKAGE | TABLET | 14 | 12 | |
| 51803-001-10 | IOSAT | 10 in 1 BAG | TABLET | 10 | 12 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 51803-001-01 | EA - Each | 51803-001 | 6a5ba3f9-288b-4d2f-a7eb-b1ccadabcf52 | 1 | 2017-03-06 |
| 51803-001-10 | EA - Each | 51803-001 | f65923a6-f4ec-4d13-b221-8a00531581ba | 1 | 2020-02-13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| POTASSIUM IODIDE | ACTIVE INGREDIENT | 1C4QK22F9J | 2 | |
| IODIDE ION | ACTIVE MOIETY | 09G4I6V86Q | 2 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 2 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 | |
| SODIUM THIOSULFATE ANHYDROUS | INACTIVE INGREDIENT | L0IYT1O31N | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51803-001 | 51803-001-01, 51803-001-10 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CELLULOSE, MICROCRYSTALLINE | OP1R32D61U | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| SODIUM THIOSULFATE ANHYDROUS | L0IYT1O31N | IACT |
| POTASSIUM IODIDE | 1C4QK22F9J | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM THIOSULFATE ANHYDROUS | SODIUM THIOSULFATE ANHYDROUS | L0IYT1O31N | TABLET / ORAL | 0.06 mg | ||
| SODIUM THIOSULFATE ANHYDROUS | SODIUM THIOSULFATE ANHYDROUS | L0IYT1O31N | TABLET / ORAL | 0.06 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| SODIUM THIOSULFATE ANHYDROUS | SODIUM THIOSULFATE ANHYDROUS | L0IYT1O31N | TABLET / ORAL | 0.06 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N018664-001 | IOSAT | POTASSIUM IODIDE | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | |
| N018664-002 | IOSAT | POTASSIUM IODIDE | 65MG | TABLET / ORAL | RLD | 2011-05-12 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N018664-001 | IOSAT | 130MG | TABLET / ORAL | RLD, RS | 1982-10-14 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N018664-002 | IOSAT | 65MG | TABLET / ORAL | RLD | 2011-05-12 | 74a2ff9319b5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| IOSAT | POTASSIUM IODIDE | Anbex Inc. | ea98aef8-93b6-4fac-be35-eb17a1a04a92 | 2025-10-03 | Warnings | 51803-001-01 51803-001-10 51803-001 51803000110 51803000101 40435397-14e1-e00c-e063-6294a90a3262 ea98aef8-93b6-4fac-be35-eb17a1a04a92 |
Adverse event summaries are temporarily unavailable. Other product information remains available.